Guggenheim raised the firm’s price target on uniQure (QURE) to $95 from $28 and keeps a Buy rating on the shares following a “compelling” 36-month readout from AMT-130. The data demonstrating a substantial slowing in Huntington’s disease “represent the best-case outcome,” the analyst tells investors. These data, along with the concordant impact on secondary endpoints, positions AMT-130 for accelerated if not full approval during 2026, the analyst contends.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- uniQure price target raised to $60 from $30 at Mizuho
- uniQure price target raised to $65 from $30 at Wells Fargo
- UniQure (QURE) Stock Jumps 248% on Huntington’s Trial Results. Analysts Raise Price Targets
- uniQure Announces Positive Results for Huntington’s Study
- uniQure Secures $175 Million Loan Amendment